<code id='938680BB41'></code><style id='938680BB41'></style>
    • <acronym id='938680BB41'></acronym>
      <center id='938680BB41'><center id='938680BB41'><tfoot id='938680BB41'></tfoot></center><abbr id='938680BB41'><dir id='938680BB41'><tfoot id='938680BB41'></tfoot><noframes id='938680BB41'>

    • <optgroup id='938680BB41'><strike id='938680BB41'><sup id='938680BB41'></sup></strike><code id='938680BB41'></code></optgroup>
        1. <b id='938680BB41'><label id='938680BB41'><select id='938680BB41'><dt id='938680BB41'><span id='938680BB41'></span></dt></select></label></b><u id='938680BB41'></u>
          <i id='938680BB41'><strike id='938680BB41'><tt id='938680BB41'><pre id='938680BB41'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:448
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024
          JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

          EricTokatisco-presidentofinvestmentbankingatCenterviewPartners.CourtesyCenterviewPartnersSANFRANCISC

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Arena BioWorks launches in Cambridge to speed drug discovery

          DavidL.Ryan/BostonGlobeAteamofhigh-poweredscientistsandbillionaireinvestorssaidFridaythatthey’relaun